Navigation Links
Ovarian cancer patients have lower mortality rates when treated at high-volume hospitals
Date:11/8/2012

New York, NY (Nov. 8, 2012) A study by researchers at the Herbert Irving Comprehensive Cancer Center (HICCC) at NewYork-Presbyterian/Columbia University Medical Center, recently e-published ahead of print by the Journal of Clinical Oncology, suggests that women who have surgery for ovarian cancer at high-volume hospitals have superior outcomes than similar patients at low-volume hospitals.

The improved survival rate is not dependent on a lower rate of complications following surgery, but on the treatment of the complications. In fact, patients with a complication after surgery at a low-volume hospital are nearly 50 percent more likely to die as a result of the complication than patients seen at high-volume hospitals.

"It is widely documented that surgical volume has an important effect on outcomes following surgery," said lead author Jason D. Wright, MD, the Levine Family Assistant Professor of Women's Health and the Florence Irving Assistant Professor of Obstetrics and Gynecology at CUMC, a gynecologic oncologist at NYP/Columbia, and a member of the HICCC.

"We examined three specific areas: the influence of hospital volume on complications, failure to rescue from complications, and inpatient mortality in ovarian cancer patients who underwent cancer-related surgery," said Dr. Wright. "But the mortality rate did not coincide with the complication rate. For women who experienced a complication at a low-volume hospital, the mortality rate was 8 percent. For women at a high-volume hospital, it was 4.9 percent. After adjusting for variables, we concluded that the failure-to-rescue rate was 48 percent higher at low-volume hospitals than at high-volume hospitals. In short, high-volume hospitals are better able to rescue patients with complications following ovarian cancer surgery."

The researchers used National Inpatient Sample data from 1998 to 2009, specifically, women aged 18 to 90 with ovarian cancer who under oophorectomy (removal of one or both ovaries): a total of more than 36,000 patients treated at 1,166 hospitals. After reviewing the data, the researchers noted several significant trends. For example, the complication rate increased with surgical volume: 20.4 percent for patients at low-volume hospitals, compared with 24.6 percent at high-volume hospitals.

Although the researchers could not account for all possible factors influencing these findingsthe NIS lacks data on physician characteristics and does not have data covering all US hospitals, for exampletheir findings have important implications for the care of patients with ovarian cancer.

"Our findings suggest that targeted initiatives to improve the care of patients with complications can improve outcomes," said Dawn L. Hershman, MD, associate professor of medicine and epidemiology at CUMC, an oncologist at NYP/Columbia, co-leader of the Breast Cancer Program at the HICCC, and a co-author of the study. "We also believe in the importance of adhering to quality guidelines and best practices, which may overcome these volume-based disparities.

"And at the most basic level, the findings highlight the importance of preventing complications to begin with. They increase mortality, in the worst-case scenario, but can also cause long-term medical problems, with patients and families facing difficult treatment choices and additional costs," said Dr. Hershman.


'/>"/>

Contact: CUMC Communications
cumcnews@columbia.edu
212-305-3900
Columbia University Medical Center
Source:Eurekalert

Related medicine news :

1. Simple ovarian cancer symptom survey that checks for 6 warning signs may improve early detection
2. U.S. Panel Rejects Ovarian Cancer Screens for Low-Risk Women
3. Mechanisms of acquired chemoresistance in ovarian cancer identified
4. Benefit of PET and PET/CT in ovarian cancer is not proven
5. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
6. Fertility preservation with cryopreservation of ovarian tissue: from experimental to mainstream
7. The prevention of hereditary breast and ovarian cancer by PGD is feasible
8. Internationally known expert in ovarian cancer to be honored at the ASCO Annual Meeting
9. UC Irvine study finds racial, economic disparities in ovarian cancer care, survival
10. U.S. Panel Rejects Ovarian Cancer Screening
11. Taller, Heavier Women May Face Higher Ovarian Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... ... launched the #perioddrama campaign to mark Menstrual Hygiene Day on May 28 and raise awareness ... not have access to a toilet, even when they’re on their periods. , WaterAid asked ... hilarious) results help shine a light on the awkwardness that women face while menstruating, even ...
(Date:5/24/2016)... MA (PRWEB) , ... May 24, 2016 , ... ... Harvard Medical School, today announced a licensing relationship that will deliver a new ... This relationship will put the medical knowledge and expertise of Harvard Medical ...
(Date:5/24/2016)... ... May 24, 2016 , ... ... and safety labels , has been featured in the National Electrical ... The eiXtra e-newsletter provides electroindustry professionals with manufacturer, regulatory, and standardization news. The ...
(Date:5/24/2016)... ... ... After graduating from Cornell, author Joshua Alexander was diagnosed with ... Social Security disability and staying in a group home. In “ Healing Schizoaffective : ... Press), Alexander shares how he was finally able to heal with the help of ...
(Date:5/24/2016)... ... 24, 2016 , ... Design Concepts , a national ... Quinto Sol Wheel Park’ in Pueblo, Colorado. This park was designed working with ... for this often overlooked neighborhood. Located at 609 E. 6th Street, Pueblo’s newest ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 Celsion Corporation ... development company, today provided an update on its ... clinical trial combining GEN-1, the Company,s DNA-based immunotherapy, ... of newly-diagnosed patients with advanced ovarian cancer who ... surgery.  GEN-1 is an IL-12 DNA plasmid vector ...
(Date:5/24/2016)... KONG , May 24, 2016 ... stent de doble terapia del mundo, introduce catéteres ... arteriovenosa. OrbusNeich, una compañía global especializada ... las vidas, ha expandido su cartera incluyendo productos ... balón JADE™ y Scoreflex™ PTA son los dispositivos ...
(Date:5/24/2016)... Dutch surgeons have launched a ground-breaking medical app to ... patients on a global scale. Medical professionals from Europe ... and the US have already signed up for the app, ... totally secure environment. Education  "Imagine a doctor ... a surgeon at Harvard to treat a bomb victim via live ...
Breaking Medicine Technology: